Table 5

Association between prophylaxis and discharge policies and NRM (N = 883)

Predictorn/N*HR (95% CI)PAdjusted HR (95% CI)Adjusted P†
Institution policy      
Prophylaxis      
 Any antibacterial 3/115 0.84 (0.25-2.77) .770 0.69 (0.16-2.97) .618 
 Penicillin or vancomycin 3/70 1.36 (0.41-4.51) .613 1.24 (0.29-5.33) .775 
 Any antifungal 22/722 0.80 (0.33-1.98) .633 0.79 (0.29-2.12) .635 
 Antimold 1/62 0.58 (0.08-4.24) .294 1.04 (0.14-7.83) .973 
 G-CSF 3/116 0.80 (0.24-2.67) .722 0.89 (0.27-3.02) .857 
Discharge policy‡      
 No discharge after chemotherapy 15/563 0.62 (0.30-1.31) .211 0.60 (0.26-1.36) .220 
Predictorn/N*HR (95% CI)PAdjusted HR (95% CI)Adjusted P†
Institution policy      
Prophylaxis      
 Any antibacterial 3/115 0.84 (0.25-2.77) .770 0.69 (0.16-2.97) .618 
 Penicillin or vancomycin 3/70 1.36 (0.41-4.51) .613 1.24 (0.29-5.33) .775 
 Any antifungal 22/722 0.80 (0.33-1.98) .633 0.79 (0.29-2.12) .635 
 Antimold 1/62 0.58 (0.08-4.24) .294 1.04 (0.14-7.83) .973 
 G-CSF 3/116 0.80 (0.24-2.67) .722 0.89 (0.27-3.02) .857 
Discharge policy‡      
 No discharge after chemotherapy 15/563 0.62 (0.30-1.31) .211 0.60 (0.26-1.36) .220 

Risk of any death during induction on or after day 10 of induction 1 or death without relapse or progressive disease during intensification. Patients censored at conditioning for stem cell transplantation. Fourteen patients not included for death or withdrawal <10 days after starting induction I. REF, reference.

*

Denominator is the number who received the intervention while the numerator is the number who experienced NRM among that those receiving the intervention.

†

Analysis adjusted for age, race, and weight group.

‡

No discharge indicates institutions that never discharge patients prior to count recovery vs those who always or sometimes discharge patients early.

View Large